In recent months, many news outlets have featured stories about the rising rates of women with breast cancer choosing elective double mastectomies. The reasons why these patients opt for healthy breast removal are very personal, but Dr. Kazuaki Takabe and Dr. Jessica Young joined us on Facebook Live to discuss the medical considerations surrounding this trend.
Over the past 14 years, Roswell Park patients, their families and friends have helped build one of the most powerful tools available to cancer researchers. Here’s how it works — and how you can help.
In December 2016, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) announced a major collaboration focused on an emerging area of cancer research: neoantigens. These small proteins on the surface of cancer cells arise from mutations often unique to a tumor, making personalized immunotherapies like cancer vaccines a possibility.
The study found that more than 42 percent of U.S. adults ages 18 to 59 have a type of genital HPV and nearly 23 percent of adults are infected with strains of the virus that carry a higher risk of causing cancer. CDC and Roswell Park recommend getting adolescents and young adults vaccinated.
When it comes to medical treatments, we’re not all alike. Women and men sometimes need different dosages of the same drug. One drug for heart failure works very well in black patients but not in white patients.
Are you the research partner a Roswell Park scientist is looking for? You might be — even if you don’t have a degree in biochemistry or cellular biology.
Rowell Park is exploding in growth, in excitement; we have so many great things to look forward to. One of my visions for the future is that our immunotherapy research and treatments will make us the go-to place for patients that wish to receive innovative cancer therapies.
You may not realize it, but your body is home to a lot of microbes — way more than you might think. In healthy humans, “microbial cells outnumber human cells by about ten to one,” according to the Human Microbiome Project of the National Institutes of Health.
The U.S. Food and Drug Administration approved a new indication for the oral drug lenalidomide (brand name Revlimid) as a maintenance therapy for multiple myeloma patients following autologous hematopoietic stem cell transplant (ASCT), also known as autologous blood and marrow transplant (BMT).